Condition Guide

Medications for Type 2 Diabetes

ICD-10: E11

Medically Reviewed by Dr. Sarah Chen, PharmD, BCPS

Clinical Pharmacist & Medical Reviewer

Last reviewed: March 19, 2026

Key Takeaways

  • Metformin remains the preferred first-line pharmacologic agent for most patients with type 2 diabetes due to its efficacy, safety, and low cost.
  • GLP-1 receptor agonists and SGLT-2 inhibitors have demonstrated cardiovascular and renal benefits beyond glucose lowering and are preferred add-on agents in high-risk patients.
  • HbA1c goal for most adults is <7%, though individualized targets (6.5–8%) are appropriate based on age, comorbidities, and hypoglycemia risk.
  • SGLT-2 inhibitors reduce hospitalizations for heart failure and slow CKD progression — benefits independent of glucose control.
  • Generic metformin costs $4–$10/month; newer agents (GLP-1 agonists, SGLT-2 inhibitors) can cost $500–$900/month without insurance.

Overview

Type 2 diabetes is the most common form of diabetes, accounting for 90–95% of all diabetes cases. It develops when the body becomes resistant to insulin or doesn't produce enough insulin to maintain normal blood glucose levels.

Treatment Overview

Treatment includes lifestyle modifications (diet, exercise, weight loss) and medications. Metformin is the first-line drug therapy. Additional medications are added as needed to achieve blood sugar targets.

23

Total Medications

3

Drug Classes

5

Off-Label Uses

Drug Classes for Type 2 Diabetes

Pharmacist-reviewed overview of each medication class, how it works, and when it's used.

Biguanides

Metformin

First-LineGeneric Available

Mechanism of Action

Primarily reduces hepatic glucose production (gluconeogenesis) by activating AMPK. Also improves peripheral insulin sensitivity. Does not stimulate insulin secretion and carries no hypoglycemia risk as monotherapy.

Common Examples

Metformin (Glucophage)Metformin ER (Glucophage XR)Metformin/sitagliptin (Janumet)

Clinical Notes

First-line for all patients without contraindications. Reduces HbA1c by 1–2%. Hold before contrast procedures and in acute illness. Extended-release formulation reduces GI side effects.

Common Side Effects

  • GI upset (nausea, diarrhea) — usually transient
  • Vitamin B12 deficiency with long-term use
  • Lactic acidosis (rare, mainly in renal impairment)

GLP-1 Receptor Agonists

GLP-1 RAs

First-Line

Mechanism of Action

Mimic glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Cardiovascular and renal benefits are partly independent of glucose lowering.

Common Examples

Semaglutide (Ozempic, Rybelsus)Liraglutide (Victoza)Dulaglutide (Trulicity)Tirzepatide (Mounjaro)

Clinical Notes

Preferred add-on (or first-line in high-risk patients) when ASCVD, heart failure, or CKD is present. Semaglutide and liraglutide have the strongest cardiovascular outcomes data. Tirzepatide (dual GLP-1/GIP) achieves the greatest HbA1c and weight reductions.

Common Side Effects

  • Nausea and vomiting (most common, usually transient)
  • Diarrhea
  • Injection site reactions
  • Pancreatitis (rare)
  • Thyroid C-cell tumors (rodent data; avoid in personal/family history of MTC)

SGLT-2 Inhibitors

SGLT-2i

First-Line

Mechanism of Action

Block the sodium-glucose cotransporter 2 (SGLT-2) in the proximal renal tubule, causing urinary glucose excretion of 60–80 g/day. Also reduce renal sodium reabsorption, lowering blood pressure and reducing cardiac preload.

Common Examples

Empagliflozin (Jardiance)Dapagliflozin (Farxiga)Canagliflozin (Invokana)

Clinical Notes

Preferred add-on when heart failure with reduced EF or CKD (eGFR ≥20) is present. Empagliflozin and dapagliflozin have FDA indications for heart failure regardless of diabetes status.

Common Side Effects

  • Genital mycotic infections (common)
  • UTIs
  • Euglycemic DKA (rare but serious)
  • Volume depletion
  • Lower limb amputations (canagliflozin — monitor foot care)

DPP-4 Inhibitors

Gliptins

Second-Line

Mechanism of Action

Inhibit dipeptidyl peptidase-4 (DPP-4), which normally degrades GLP-1 and GIP. By preserving endogenous incretin levels, they enhance glucose-dependent insulin secretion and suppress glucagon.

Common Examples

Sitagliptin (Januvia)Saxagliptin (Onglyza)Linagliptin (Tradjenta)Alogliptin (Nesina)

Clinical Notes

Weight-neutral and well-tolerated. Modest HbA1c reduction (0.5–0.8%). No hypoglycemia risk as monotherapy. Preferred when GLP-1 RA or SGLT-2i are not tolerated or affordable.

Common Side Effects

  • Nasopharyngitis
  • Urinary tract infections
  • Pancreatitis (rare)
  • Joint pain (rare)

Sulfonylureas

SUs

Second-LineGeneric Available

Mechanism of Action

Stimulate insulin secretion by binding to ATP-sensitive potassium channels on pancreatic beta cells, causing depolarization and calcium-dependent insulin release. Effect is glucose-independent.

Common Examples

Glipizide (Glucotrol)Glimepiride (Amaryl)Glyburide (Diabeta)

Clinical Notes

Inexpensive and effective (HbA1c reduction 1–2%), but carry risk of hypoglycemia and weight gain. Glipizide and glimepiride are preferred over glyburide (shorter half-life, lower hypoglycemia risk). Avoid glyburide in elderly patients.

Common Side Effects

  • Hypoglycemia (most significant risk)
  • Weight gain (2–4 kg)
  • Photosensitivity

All Medications

FDA-approved and commonly used medications for Type 2 Diabetes in our database.

Off-Label Uses

Lovastatin

(Lovastatin)Off-Label

LOVASTATIN (brand name: Lovastatin) is a statin (HMG-CoA reductase inhibitor). Indications and Usage Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a…

$10-$30/month

Atorvastatin

(Lipitor)Off-Label

Atorvastatin (Lipitor) is the world's best-selling prescription drug and the most widely prescribed statin for lowering LDL ('bad') cholesterol and reducing the risk of heart attack, stroke, and cardiovascular death. It is used for both primary prevention (in people without established heart disease but with risk factors) and secondary prevention (in people who have already had a heart attack or stroke). Generic atorvastatin is available for as little as $4–$25 per month.

$4–$25/month

Generic Available

Captopril

(Captopril)Off-Label

Captopril is a medication belonging to a class of drugs called ACE inhibitors, primarily used to treat high blood pressure (hypertension). It works by helping to relax blood vessels, which allows blood to flow more easily and lowers blood pressure.

$10–$40/month

Losartan Potassium

(Cozaar)Off-Label

Losartan potassium (Cozaar) is an angiotensin II receptor blocker (ARB) used to treat high blood pressure, protect the kidneys in type 2 diabetes, and reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. Unlike ACE inhibitors, losartan does not cause a dry cough and carries a significantly lower risk of angioedema. It is also the only ARB with a clinically meaningful uricosuric (uric acid-lowering) effect, making it a preferred choice in patients with hypertension and gout.

$4–$15/month

Irbesartan

(Irbesartan)Off-Label

IRBESARTAN (brand name: Irbesartan) is a ARBs. 1 INDICATIONS & USAGE Irbesartan tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) •…

$4-$25/month

How to Choose the Right Medication

Clinical decision factors used by prescribers when selecting a treatment.

  1. 1Start metformin at diagnosis unless contraindicated (eGFR <30, contrast procedure, hospitalization).
  2. 2Add a GLP-1 RA or SGLT-2i as second agent if ASCVD, heart failure, or CKD is present — regardless of HbA1c.
  3. 3Add a DPP-4 inhibitor or sulfonylurea as second agent when cost is a primary concern and cardiovascular risk is low.
  4. 4For patients needing >1.5% HbA1c reduction, tirzepatide or high-dose semaglutide are the most potent options.
  5. 5Avoid sulfonylureas in elderly patients (hypoglycemia risk) and glyburide specifically in all patients with renal impairment.
  6. 6Consider insulin when HbA1c is very high (>10–11%) or when oral agents are insufficient.

Monitoring & Follow-Up

  • Check HbA1c every 3 months until at goal, then every 6 months.
  • Monitor eGFR and potassium annually (or more frequently) in patients on SGLT-2i or ACEi/ARB.
  • Foot exams and dilated eye exams annually.
  • Educate on hypoglycemia recognition and treatment (15 g fast-acting carbohydrates) for patients on sulfonylureas or insulin.

Find the lowest price for any medication

Real-time prices at 67,000+ pharmacies · Free · No sign-up

Frequently Asked Questions

What is the difference between type 1 and type 2 diabetes?

Type 1 diabetes is an autoimmune condition where the body destroys insulin-producing cells. Type 2 is characterized by insulin resistance and relative insulin deficiency, strongly associated with lifestyle factors and genetics.

What is the difference between Ozempic and Mounjaro?

Both are injectable medications used for type 2 diabetes, but they work differently. Ozempic (semaglutide) is a GLP-1 receptor agonist — it activates one hormone receptor. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist — it activates two hormone receptors simultaneously. Clinical trials show tirzepatide achieves greater HbA1c reduction and weight loss than semaglutide. Both have weekly dosing schedules. See our full comparison: Mounjaro vs. Ozempic.

Can type 2 diabetes be reversed with medication?

Type 2 diabetes can go into remission (HbA1c <6.5% without medication) through significant weight loss — typically 10–15% of body weight. Bariatric surgery achieves remission in 50–80% of patients. GLP-1 receptor agonists and tirzepatide, which cause substantial weight loss, have also been associated with remission in some patients. However, 'reversal' requires sustained lifestyle changes; the underlying metabolic predisposition remains.

GLP-1 Muscle Protection · Sponsored

Protect your muscle mass while taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro)

GLP-1 medications can cause up to 39% muscle loss alongside fat. Zova's AI-powered protocol — backed by Lancet Diabetes & Endocrinology research — reduces that to just 8.7% through leucine tracking and injection-day adaptive nutrition.

39%standard GLP-1
8.7%Zova Protocol
muscle loss
Join the Waitlist — Free

No credit card. No commitment.

Get the RxGo app — free prescription discounts on the go

Works at 67,000+ pharmacies · No membership needed

Download

Medical Disclaimer

The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.